Immunomodulation by roquinimex decreases the expression of IL-23 (p19) mRNA in the brains of herpes simplex virus type 1 infected BALB/c mice

Clinical and Experimental Immunology

Volumn 137, Issue 2, 2004, Pages 305-312

  Peltoniemi, J ^a,c   Broberg, E K ^a,b,c   Halenius, A ^d   Setala N ^a,c   Eralinna J P ^c   Salmi, A A ^a   Roytta M ^a   Hukkanen, V ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Cytokines; Herpes simplex virus; Immunomodulation; Roquinimex

Indexed keywords

GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 23; INTERLEUKIN 4; MESSENGER RNA; PNU 212616; ROQUINIMEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM INFECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; STATISTICAL SIGNIFICANCE; TH1 CELL; TRIGEMINUS GANGLION; VIRUS VIRULENCE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BRAIN; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HERPESVIRUS 1, HUMAN; HYDROXYQUINOLINES; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; INTERLEUKINS; KERATITIS, HERPETIC; MICE; RNA, MESSENGER;

EID: 3543026931     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02528.x     Document Type: Article

References (40)

1. Whitley RJ. Herpes simplex viruses. In: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, Straus SE, eds. Fields Virology, 4th edn. Philadelphia: Lippincott, Williams & Wilkins 2001:2461-09.
2. Roizman B, Knipe DM. Herpes simplex viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, Martin MA, Lamb RA, Roizman B, Straus SE, eds. Fields Virology, 4th edn. Philadelphia: Lippincott, Williams & Wilkins 2001:2399-459.
3. Hukkanen V, Broberg E, Erälinna J-P, Salmi A. Cytokines in experimental herpes simplex virus infection. Int Rev Immunol 2002; 21:1-17.
4. Simmons A, Tscharke D, Speck P. The role of immune mechanisms in control of herpes simplex virus infection of the peripheral nervous system. Curr Top Microbiol Immunol 1992; 179:31-56.
5. Kodukula P, Liu T, Rooijen NV, Jager MJ, Hendricks RL. Macrophage control of herpes simplex virus type 1 replication in the peripheral nervous system. J Immunol 1999; 162:2895-905.
6. Cantin EM, Hinton DR, Chen J, Openshaw H. Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J Virol 1995; 69:4898-905.
7. Cantin E, Tanamachi B, Openshaw H. Role for gamma interferon in control of herpes simplex virus type 1 reactivation. J Virol 1999; 73:3418-23.
8. Lekstrom-Himes JA, LeBlanc RA, Pesnicak L, Godleski M, Straus SE. Gamma interferon impedes the establishment of herpes simplex virus type 1 latent infection but has no impact on its maintenance or reactivation in mice. J Virol 2000; 74:6680-3.
9. Al-Khatib K, Campbell IL, Carr DJJ. Resistance to ocular herpes simplex virus type 1 infection in IL-12 transgenic mice. J Neuroimmunol 2002; 132:41-8.
10. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46.
11. Oppmann B, Lesley R, Blom B et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13:715-25.
12. Broberg E, Setälä N, Erälinna J-P, Salmi A, Röyttä M, Hukkanen V. Herpes simplex virus type 1 infection induces upregulation of IL-23 (p19) mRNA expression in trigeminal ganglia of BALB/c mice. J Interferon Cytokine Res 2002; 22:641-51.
13. Kastrukoff L, Lau A, Puterman M. Genetics of natural resistance to herpes simplex virus type 1 latent infection of the peripheral nervous system in mice. J General Virol 1986; 67:613-21.
14. Shimeld C, Efstathiou, Hill T. Tracking the spread of a lacZ-tagged herpes simplex virus type 1 between the eye and the nervous system of the mouse: comparison of primary and recurrent infection. J Virol 2001; 75:5252-62.
15. Hedlund G, Link H, Zhu J, Xiao BG. Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system. Int Immunopharmacol 2001; 1:1123-30.
16. Gross DJ, Weiss L, Reibstein I, Hedlund G, Dahlen E, Rapoport MJ, Slavin S. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus. Int Immunopharmacol 2001; 1:1131-9.
17. Lehmann D, Karussis DM, Fluresco D, Mizrachi-Koll R, Ovadia H, Shezen E, Kalland T, Abramsky O. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J Neuroimmunol 1997; 74:102-10.
18. Dahlen E, Andersson M, Dawe K, Tellander AC, Brunmark C, Bjork A, Hedlund G. Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages. Autoimmunity 2000; 32:199-211.
19. Arad G, Katzenellenbogen M, Levy R, Slavin S, Kaempfer R. Linomide, an immunomodulator that inhibits Th1 cytokine gene expression. Int Immunol 1996; 8:1603-7.
20. Peltoniemi J, Setälä N, Broberg E, Röyttä M, Hukkanen V, Salmi AA, Erälinna J-P. Semliki Forest virus infection is enhanced in Th1-prone SJL mice but not inTh2-prone BALB/c mice during Linomide-induced immunomodulation. J Neuroimmunol 2002; 132:83-92.
21. Karussis D, Abramsky O, Rosenthal Y, Mizrachi-Koll R, Ovadia H. Linomide downregulates autoimmunity through induction of TH2 cytokine production by lymphocytes. Immunol Lett 1999; 67:203-8.
22. Erälinna J-P, Röyttä M, Hukkanen V, Zinhu D, Salmi AA, Salonen R. Selective downregulation of Th1 response by Linomide reduces autoimmunity but increases susceptibility to viral infection in BALB/c and SJL mice. J Neuroimmunol 1998; 88:165-76.
23. Karussis DM, Lehmann D, Slavin S et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol 1993; 34:654-60.
24. Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Kalland T, Abramsky O. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA 1993; 98:6400-4.
25. Ziegler T, Waris M, Rautiainen M, Arstila P. Herpes simplex virus detection by macroscopic reading after overnight incubation and immunoperoxidase staining. J Clin Microbiol 1988; 26:2013-7.
26. Hukkanen V, Heino P, Sears A, Roizman B. Detection of herpes simplex virus latency-associated RNA in mouse trigeminal ganglia by in situ hybridization using nonradioactive digoxigenin-labeled DNA and RNA probes. Meth Mol Cell Biol 1990; 2:70-81.
27. Halminen M, Klemetti P, Vaarala O, Hurme M, Ilonen J. Interferon-γ production in antigen specific T cell response: Quantitation of specific mRNA and secreted protein. Scand J Immunol 1997; 46:388-92.
28. Broberg EK, Nygårdas M, Salmi AA, Hukkanen V. Low copy number detection of herpes simplex virus type 1 mRNA and mouse Th1 cytokine mRNAs by Light Cycler quantitative real-time PCR. J Virol Meth 2003; 112:53-65.
29. Broberg E, Setälä N, Röyttä M, Salmi AA, Erälinna J-P, He B, Roizman B, Hukkanen V. Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther 2001; 8:769-77.
30. Pirhonen J, Matikainen S, Julkunen I. Regulation of virus-induced IL-12 and IL-23 expression in human macrophages. J Immunol 2002; 169:5673-8.
31. Cua DJ, Sherlock J, Chen Y et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003; 421:744-8.
32. Brunmark C, Runstrom A, Ohlsson L, Sparre B, Brodin T, Astrom M, Hedlund G. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J Neuroimmunol 2002; 130:163-72.
33. He J, Ichimura H, Iida TM et al. Kinetics of cytokine production in the cornea and trigeminal ganglion of C57BL/6 mice after corneal HSV-1 infection. J Interferon Cytokine Res 1999; 19:609-15.
34. Cantin E, Tanamachi B, Openshaw T, Mann J, Clarke K. Gamma interferon receptor null-mutant mice are more susceptible to herpes simlex virus type 1 infection than gamma interferon ligand null-mutant mice. J Virol 1999; 73:5196-200.
35. Carreno BM, Collins M. The B7 family of ligands and its receptors. New Pathways for costimulation and inhibition of immune responses. Annu Rev Immunol; 2002; 20:29-53.
36. Aarnisalo J, Ilonen J, Vainionpää R, Volanen I, Kaitosaari T, Simell O. Development of antibodies against cytomegalovirus, varicellazoster virus and herpes simplex virus in Finland during the first eight years of life: a prospective study. Scand J Infect Dis 2003; 35:750-3.
37. Kastrukoff LF, Lau AS, Leung GY, Thomas EE. Contrasting effects of immunosuppression on herpes simplex virus type I (HSV I) induced central nervous system (CNS) demyelination in mice. J Neurol Sci 1993; 117:148-58.
38. Bernstein DI, Miller RL, Harrison CJ. Effects of therapy with an immunomodulator (imiquimod, R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development. Antiviral Res 1993; 20:45-55.
39. Harrison CJ, Miller RL. Bernstein DI. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs. Antimicrob Agents Chemother 1994; 38:2059-64.
40. Harrison CJ, Miller RL, Bernstein DI. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine 2001; 19:1820-6.